Top

Drug Safety

Published in:

01-09-2007 | Practical Drug Safety

Thiazolidinediones and their Fluid-Related Adverse Effects

Facts, Fiction and Putative Management Strategies

Authors: Dr Janaka Karalliedde, Robin E. Buckingham

Published in: Drug Safety | Issue 9/2007

Abstract

Thiazolidinediones (TZDs) or glitazones are agents that are widely used for the treatment of type 2 diabetes mellitus. These drugs have a multitude of therapeutic effects including reduction in insulin resistance and hyperglycaemia, anti-inflammatory effects and amelioration of hypertension, microalbuminuria and hepatic steatosis.

The TZD molecular target, peroxisome proliferator-activated receptor γ (PPARγ), a nuclear transcription factor, is expressed diffusely in humans, including many tissues comprising the cardiovascular and renal systems. This suggests a potential for TZDs to elicit perturbing effects on these systems, which are independent of their effects on glucose and lipid metabolism.

One of the most common adverse effects of TZDs is fluid retention, which can result in, or exacerbate, oedema and congestive heart failure (CHF). The frequency of peripheral oedema is approximately 5% when TZDs are used in mono-or combination oral therapy, and about 15% when used with insulin.

Patients with type 2 diabetes are at high risk of myriad morbid complications, including CHF. The development of CHF, particularly in the elderly, is a harbinger of premature mortality. TZD-induced oedema is largely peripheral, may have its origins in changes in haemodynamics, with some contribution from molecules, which regulate cell and tissue permeability (e.g. vascular endothelial growth factor and protein kinase Cβ), and remains the preponderant manifestation of TZD-induced fluid retention even in those with existing heart failure. Preclinical and pilot clinical data attest to the fact that at least part of the fluid retention derives from a direct effect of TZDs on sodium reabsorption via the renal medullary collecting duct, a mechanism that is sensitive to diuretic agents that have this nephron segment as their site of action, in whole or in part (spironolactone, amiloride and hydrochlorothiazide). Our review suggests various potential clinical strategies by which TZD-induced fluid retention might be effectively monitored and addressed.

Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 1995 Jun 2; 270(22): 12953–6PubMedCrossRef

Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 2005; 41(2): 237–46PubMedCrossRef

Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003; 38(4): 1008–17PubMed

Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for non-alcoholic steatohepatitis. Hepatology 2004; 39(1): 188–96PubMedCrossRef

Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001; 24(4): 710–9PubMedCrossRef

Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 2001; 44(12): 2210–9PubMedCrossRef

Reaven GA. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595–607PubMedCrossRef

Giusti V, Verdumo C, Suter M, et al. Expression of peroxisome proliferator-activated receptor-γ1 and peroxisome proliferator-activated receptor-γ2 in visceral and subcutaneous adipose tissue of obese women. Diabetes 2003; 52(7): 1673–6PubMedCrossRef

The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006 Sept 23; 368(9541): 1096–105CrossRef

10.

Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006 Dec 7; 355(23): 2427–43PubMedCrossRef

11.

Nakamura T, Ushiyama C, Osada S, et al. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001; 50(10): 1193–6PubMedCrossRef

12.

Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17: 7–12PubMedCrossRef

13.

Natali A, Baldeweg S, Toschi E, et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004; 27(6): 1349–57PubMedCrossRef

14.

Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005 May 17; 111(19): 2525–31PubMedCrossRef

15.

Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26(9): 2493–9PubMedCrossRef

16.

Marfella R, D’Amico M, Esposito K, et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes 2006; 55(3): 622–32PubMedCrossRef

17.

Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macro Vascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366(9493): 1279–89PubMedCrossRef

18.

Sauer WH, Cappola AR, Berlin JA, et al. Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Am J Cardiol 2006; 97(5): 651–4PubMedCrossRef

19.

Wilcox R, Bousser M-G, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04). Stroke 2007; 38(3): 865–73PubMedCrossRef

20.

Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91(9): 3349–54PubMedCrossRef

21.

Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100(12): 3149–53PubMedCrossRef

22.

Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87(6): 2784–91PubMedCrossRef

23.

Kolak M, Yki-Jarvinen H, Kannisto K, et al. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab 2007; 92(2): 720–4PubMedCrossRef

24.

Nichols GA, Hillier TA, Erbey JR, et al. Congestive heart failure in type 2 diabetes. Diabetes Care 2001; 24(9): 1614–9 752PubMedCrossRef

25.

Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002 Aug 1; 347(5): 305–13PubMedCrossRef

26.

Li X, Li S, Ulusoy E, et al. Childhood adiposity as a predictor of cardiac mass in adulthood: the Bogalusa Heart Study. Circulation 2004 Nov 30; 110(922): 3488–92PubMedCrossRef

27.

Chinali M, de Simone G, Roman MJ, et al. Impact of obesity on cardiac geometry and function in a population of adolescents: the Strong Heart Study. J Am Coll Cardiol 2006 Jun 6; 47(11): 2267–73PubMedCrossRef

28.

Arnlov J, Lind L, Zethelius B, et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J 2001; 142(4): 720–4PubMedCrossRef

29.

Ingelsson E, Sundstrom J, Arnlov J, et al. Insulin resistance and risk of congestive heart failure. JAMA 2005 Jul 20; 294(3): 334–41PubMedCrossRef

30.

Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997; 30(2): 527–32PubMedCrossRef

31.

Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005 Sep 20; 46(6): 1019–26PubMedCrossRef

32.

Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham Study. Am J Cardiol 1974 Jul; 34(1): 29–34PubMedCrossRef

33.

Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001 Jun 5; 103(22): 2668–73PubMedCrossRef

34.

SmithKline Beecham Pharmaceuticals. Avandia (rosiglitazone) [package insert]. Philadelphia (PA): SmithKline Beecham Pharmaceuticals, 2001

35.

Takeda Pharmaceuticals, Inc. Actos (pioglitazone) [package insert]. Lincolnshire (IL): Takeda Pharmaceuticals, Inc., 2000

36.

Rennings AJM, Smits P, Stewart MW, et al. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care 2006; 29(3): 581–7PubMedCrossRef

37.

Basu A, Jensen MD, McCann F, et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006; 29(3): 510–4PubMedCrossRef

38.

Karalliedde J, Buckingham R, Starkie M, et al. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006; 17(12): 3482–90PubMedCrossRef

39.

Nagasawa E, Abe Y, Nishimura J, et al. Pivotal role of peroxisome proliferator-activated receptor γ (PPARγ) in regulation of erythroid progenitor cell proliferation and differentiation. Exp Hematol 2005; 33(8): 857–64PubMedCrossRef

40.

Raji A, Seely EW, Bekins SA, et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26(1): 172–8PubMedCrossRef

41.

Gerber P, Lubben G, Heusler S, et al. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin 2003; 19(6): 532–9PubMedCrossRef

42.

Zanchi A, Chiolero A, Maillard M, et al. Effects of the peroxisomal proliferator-activated receptor-γ agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004; 89(3): 1140–5PubMedCrossRef

43.

Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med 2005; 11(8): 861–6PubMedCrossRef

44.

Zhang H, Zhang A, Kohan DE, et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci 2005 Jun 28; 102(26): 9406–11PubMedCrossRef

45.

Kleyman TR, Cragoe EJ. Amiloride and its analogs as tools in the study of ion transport. J Membrane Biol 1988; 105(1): 1–21CrossRef

46.

Hong G, Lockhart A, Davis B, et al. PPARγ activation enhances cell surface ENaCα via up-regulation of SGK1 in human collecting duct cells. FASEB J 2003; 17(13): 1966–8PubMed

47.

Kalambokis GN, Tsatsoulis AA, Tsianos EV. The edematogenic properties of insulin. Am J Kidney Dis 2004; 44(4): 575–90PubMed

48.

Raji A, Gerhard-Herman MD, Williams JS, et al. Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians. Diabet Med 2006; 23(5): 537–43PubMedCrossRef

49.

Wang J, Barbry P, Maiyar AC, et al. SGK integrates insulin and mineralocorticoid regulation of epithelial sodium transport. Am J Physiol Renal Physiol 2001; 280(2): F303–13PubMed

50.

Nofziger C, Chen L, Shane MA, et al. PPARγ agonists do not directly enhance basal or insulin-stimulated Na⁺ transport via the epithelial Na⁺ channel. Pflugers Arch 2005; 451(3): 445–53PubMedCrossRef

51.

Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24(7): 1226–32PubMedCrossRef

52.

Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56(4): 251–7PubMed

53.

Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002; 22(7): 924–9PubMedCrossRef

54.

Tang WHW, Francis GS, Hoogwerf BJ, et al. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003 Apr 16; 41(8): 1394–8PubMedCrossRef

55.

Yamakawa K, Hosoi M, Koyama H, et al. Peroxisome proliferator-activated receptor-γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Comm 2000 May 19; 271(3): 571–4PubMedCrossRef

56.

Emoto M, Fukuda N, Nakamori Y, et al. Plasma concentrations of vascular endothelial growth factor are associated with peripheral oedema in patients treated with thiazolidinedione. Diabetologia 2006; 49(9): 2217–8PubMedCrossRef

57.

Sotiropoulos KB, Clermont A, Yasuda Y, et al. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARγ agonist’s effects on edema and weight gain. FASEB J 2006; 20(6): E367–80

58.

Coluciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol 2003; 123(9): 1273–5CrossRef

59.

Ryan EH, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina 2006; 26(5): 562–70PubMedCrossRef

60.

Delea TE, Edelsberg JS, Hagiwara M. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003; 26(11): 2983–9PubMedCrossRef

61.

Karter AJ, Ahmed AT, Liu J, et al. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 2005; 22(8): 986–93 753PubMedCrossRef

62.

Rajagopalan R, Rosenson RS, Fernandes AW, et al. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther 2004; 26(9): 1400–10PubMedCrossRef

63.

Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003; 78(9): 1088–91PubMedCrossRef

64.

Srivastava PM, Calafiore P, MacIsaac RJ, et al. Thiazolidinediones and congestive heart failure-exacerbation or new onset of left ventricular dysfunction? Diabet Med 2004; 21(8): 945–50PubMedCrossRef

65.

St John-Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25(11): 2058–64CrossRef

66.

Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111(5): 583–90PubMedCrossRef

67.

Inzucchi SE, Masoudi FA, Wang Y, et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction. Diabetes Care 2005; 28(7): 1680–9PubMedCrossRef

68.

Buckingham RE, Hanna A. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? Diabetes Obes Metab (OnlineEarly Articles). Epub 2007 Jan 16

69.

Reynolds LR, Konz EC, Frederich RC, et al. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4(4): 270–5PubMedCrossRef

70.

Asnani S, Richard BC, Desouza C, et al. Is weight loss possible in patients treated with thiazolidindiones? Experience with a low-calorie diet. Curr Med Res Opin 2003; 19(7): 609–13PubMedCrossRef

71.

Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003 Dec 9; 108(23): 2941–8PubMedCrossRef

72.

Iwanaga Y, Nishi I, Furuichi S, et al. B-Type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure. J Am Coll Cardiol 2006; 47(4): 742–8PubMedCrossRef

73.

Bhalla MA, Chiang A, Epshteyn VA, et al. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 2004; 44(5): 1047–52PubMedCrossRef

74.

Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004 Feb 10; 109(5): 594–600PubMedCrossRef

75.

Horwich TB, Hamilton MA, Fonarow GC. B-Type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006; 47(1): 85–90PubMedCrossRef

76.

Tsutamoto T, Wada A, Sakai H, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2006; 47(3): 582–6PubMedCrossRef

77.

Ogawa S, Takeuchi K, Ito S. Plasma BNP levels in the treatment of type 2 diabetes with pioglitazone. J Clin Endocrinol Metab 2003; 88(8): 3993–6PubMedCrossRef

78.

Dargie H, Hildebrandt PR, Riegger G, et al. Baseline B-type natriuretic peptide identifies patients with type 2 diabetes and class I/II heart failure at risk of fluid retention when treated with rosiglitazone [abstract no. 1048-173]. J Am Coll Cardiol 2005 Feb 1; 45 (3 Suppl. A): 139A

79.

Hansen L, Ekstrom CT, Palacios RT, et al. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-γ/α agonist-induced edema in type 2 diabetic patients. J Clin Endocrinol Metab 2006; 91(9): 3446–50PubMedCrossRef

80.

Gregersen MI. Blood volume. Physiol Rev 1958; 39: 307–42

81.

Dill DB, Costill DL. Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. J Appl Physiol 1974; 37: 247–8PubMed

82.

Wilson DR, Honrath U, Sonnenberg H. Thiazide diuretic effect on medullary collecting duct function in the rat. Kidney Int 1983; 23: 711–6PubMedCrossRef

83.

Kim G-H, Masilamani S, Turner R, et al. The thiazide-sensitive Na-Cl cotransporter is an aldosterone-induced protein. Proc Natl Acad Sci U S A 1998; 95(11): 14552–7PubMedCrossRef

84.

Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol 2003; 284(1): F11–21PubMed

85.

Boden G, Homko C, Mozzoli M, et al. Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention. Diabetes 2007; 56: 248–55PubMedCrossRef

86.

Karalliedde J, Viberti GC. Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56: 248–255 [letter]. Diabetes 2007 May; 56 (5): e3CrossRef

87.

Nissen SE, Wolski K, Topol EJ. Effect of murgalitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005; 294: 2581–6PubMedCrossRef

Title: Thiazolidinediones and their Fluid-Related Adverse Effects
Facts, Fiction and Putative Management Strategies
Authors: Dr Janaka Karalliedde
Robin E. Buckingham
Publication date: 01-09-2007
Publisher: Springer International Publishing
Published in: Drug Safety / Issue 9/2007
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200730090-00002

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Thiazolidinediones and their Fluid-Related Adverse Effects

Facts, Fiction and Putative Management Strategies

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2007

Drug-Induced Cardiovascular Disorders

Adverse Drug Event Detection in a Community Hospital Utilising Computerised Medication and Laboratory Data

Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis

Clinical Pattern of Zileuton-Associated Liver Injury

Benefit-Risk Assessment of Nesiritide in the Treatment of Acute Decompensated Heart Failure

Is There Still a Role for Aprotinin in Cardiac Surgery?